Cargando…

PPAR-γ: Therapeutic Potential for Multiple Sclerosis

The role of peroxisome proliferator-activated receptors (PPARs) in altering lipid and glucose metabolism is well established. More recent studies indicate that PPARs also play critical roles in controlling immune responses. We and others have previously demonstrated that PPAR-γ agonists modulate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Drew, Paul D., Xu, Jihong, Racke, Michael K.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2441778/
https://www.ncbi.nlm.nih.gov/pubmed/18604287
http://dx.doi.org/10.1155/2008/627463
_version_ 1782156631775117312
author Drew, Paul D.
Xu, Jihong
Racke, Michael K.
author_facet Drew, Paul D.
Xu, Jihong
Racke, Michael K.
author_sort Drew, Paul D.
collection PubMed
description The role of peroxisome proliferator-activated receptors (PPARs) in altering lipid and glucose metabolism is well established. More recent studies indicate that PPARs also play critical roles in controlling immune responses. We and others have previously demonstrated that PPAR-γ agonists modulate the development of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). This review will discuss the cellular and molecular mechanisms by which these agonists are believed to modulate disease. The therapeutic potential of PPAR-γ agonists in the treatment of multiple sclerosis will also be considered.
format Text
id pubmed-2441778
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-24417782008-07-03 PPAR-γ: Therapeutic Potential for Multiple Sclerosis Drew, Paul D. Xu, Jihong Racke, Michael K. PPAR Res Review Article The role of peroxisome proliferator-activated receptors (PPARs) in altering lipid and glucose metabolism is well established. More recent studies indicate that PPARs also play critical roles in controlling immune responses. We and others have previously demonstrated that PPAR-γ agonists modulate the development of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). This review will discuss the cellular and molecular mechanisms by which these agonists are believed to modulate disease. The therapeutic potential of PPAR-γ agonists in the treatment of multiple sclerosis will also be considered. Hindawi Publishing Corporation 2008 2008-06-29 /pmc/articles/PMC2441778/ /pubmed/18604287 http://dx.doi.org/10.1155/2008/627463 Text en Copyright © 2008 Paul D. Drew et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Drew, Paul D.
Xu, Jihong
Racke, Michael K.
PPAR-γ: Therapeutic Potential for Multiple Sclerosis
title PPAR-γ: Therapeutic Potential for Multiple Sclerosis
title_full PPAR-γ: Therapeutic Potential for Multiple Sclerosis
title_fullStr PPAR-γ: Therapeutic Potential for Multiple Sclerosis
title_full_unstemmed PPAR-γ: Therapeutic Potential for Multiple Sclerosis
title_short PPAR-γ: Therapeutic Potential for Multiple Sclerosis
title_sort ppar-γ: therapeutic potential for multiple sclerosis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2441778/
https://www.ncbi.nlm.nih.gov/pubmed/18604287
http://dx.doi.org/10.1155/2008/627463
work_keys_str_mv AT drewpauld ppargtherapeuticpotentialformultiplesclerosis
AT xujihong ppargtherapeuticpotentialformultiplesclerosis
AT rackemichaelk ppargtherapeuticpotentialformultiplesclerosis